These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21902077)

  • 41. [Briefing and accusation of medical malpractice--the second victim].
    Wienke A
    Laryngorhinootologie; 2013 Apr; 92 Suppl 1():S1-22. PubMed ID: 23625708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health technology assessment and economic evaluation: arguments for a national approach.
    Vale L
    Value Health; 2010; 13(6):859-61. PubMed ID: 20701729
    [No Abstract]   [Full Text] [Related]  

  • 46. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
    Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
    BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of the UK NHS purchaser-provider split on the 'rational' introduction of new medical technologies.
    Rosen R; Mays N
    Health Policy; 1998 Feb; 43(2):103-23. PubMed ID: 10177613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of medical technologies in Sweden.
    Jönsson B
    Soc Sci Med; 1997 Aug; 45(4):597-604. PubMed ID: 9226784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sexual healthcare must not be allowed to become "Cinderella" of NHS, warns royal college chair.
    Torjesen I
    BMJ; 2017 Apr; 357():j2118. PubMed ID: 28455455
    [No Abstract]   [Full Text] [Related]  

  • 53. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NICE guidance in the Scottish context.
    Kohli H; Tannahill A
    Scott Med J; 2009 Feb; 54(1):35-8. PubMed ID: 19291935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The which-hunt: assembling health technologies for assessment and rationing.
    Giacomini MK
    J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. At the center of health care policy making: the use of health technology assessment at NICE.
    Stevens AJ; Longson C
    Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.